What research findings does Sermorelin have regarding GH-related growth?
Average growth rate increased from 4.8 to 7.2 cm/year. Other studies report: most subjects' growth rate improved, and partial growth indicators in higher dose groups were close to GH group.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 1994 · PMID 7955460 | 18 children with idiopathic short stature; 12 months | Average growth rate increased from 4.8 to 7.2 cm/year. | 1994; short-term speed changes cannot be equated to final adult height benefits. |
| 1993 · PMID 8329826 | 43 children with hypothalamic GH deficiency; randomized comparison | Most subjects showed increased growth rate, with some growth indicators in the higher dose group approaching those in the GH group. | 1993; specific deficiencies in children, not for adult anti-aging purposes. |
| 1990 · PMID 2140733 | Children who are short in stature and have slow growth; continuous subcutaneous administration | The significance of research promoting linear growth shown in one-year follow-up. | 1990 Old paper; specific results need to be combined with the original research conditions. |
References
What was observed in the children's growth rate study?
Average growth rate increased from 4.8 to 7.2 cm/year.[1] ↗
18 children with idiopathic short stature; 12 months
1994; short-term speed changes cannot be equated to final adult height benefits.
View the Article Title and Full Citation＋
Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.
Clinical endocrinology · Volume and issue year 1994
First published 1994-10-01 · PMID 7955460.
DOI 10.1111/j.1365-2265.1994.tb02580.x
How should studies comparing GH in children’s growth be interpreted?
Most subjects showed increased growth rate, with some growth indicators in the higher dose group approaching those in the GH group.[2] ↗
43 children with hypothalamic GH deficiency; randomized comparison
1993; specific deficiencies in children, not for adult anti-aging purposes.
View the Article Title and Full Citation＋
Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.
Acta Paediatrica (Oslo, Norway: 1992). Supplement · Volume/Issue, 1993
First published 1993-03-01 · PMID 8329826.
DOI 10.1111/j.1651-2227.1993.tb12828.x
What findings are there in growth follow-up of one-year-old children?
The significance of research promoting linear growth shown in one-year follow-up.[3] ↗
Children who are short in stature and have slow growth; continuous subcutaneous administration
1990 Old paper; specific results need to be combined with the original research conditions.
View the Article Title and Full Citation＋
Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children.
Clinical endocrinology · Volume and issue year 1990
First published 1990-02-01 · PMID 2140733.
DOI 10.1111/j.1365-2265.1990.tb00851.x
Common issues and corresponding evidence
What research findings does Sermorelin have regarding GH-related growth?＋
Average growth rate increased from 4.8 to 7.2 cm/year. Other studies report: most subjects' growth rate improved, and partial growth indicators in higher dose groups were close to GH group.[1] ↗ [2] ↗
Are Sermorelin growth studies applicable to adults?＋
The classic data on this page mainly come from children who are short or have slow growth. Short-term growth improvement in children cannot directly be extrapolated to adult height increase, anti-aging, or ultimate adult height benefits.[1] ↗ [3] ↗
Sermorelin—these conclusions apply to which study populations?＋
18 children with idiopathic short stature; 12 months; 43 hypothalamic-derived GH-deficient children; randomized comparison; short stature and slow-growing children; continuous subcutaneous administration. 1994; short-term growth rate change doesn't equal final adult height benefit.[1] ↗ [2] ↗ [3] ↗
Sermorelin
Return to catalog specifications and batch file verification entry.
